Search Results

Therapeutics and Chime Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer

endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic target in cancer

fibroblast heterogeneity in fibroblast-associated diseases Ultrasensitive dose-response for asbestos cancer

4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer

News Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer

GPCRs in Oncology and Immunology GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer

Reviews, GPCRs, and more Lessons from the physiological role of guanosine in neurodegeneration and cancer

Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer

Microbiota Effects on the Immune System, and Western Diseases Lactate receptor GPR81 drives breast cancer

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers

significant challenge in drug development, particularly in the treatment of infectious diseases and cancer

Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer

Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers

Small-molecule targeting of GPCR-independent non-canonical G protein signaling inhibits cancer progression

in a mouse model of sciatic nerve injury GPCRs in Oncology and Immunology GPR37 promotes colorectal cancer

infection Industry News InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer

parahaemolyticus Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer

macrophage migration during tissue inflammation From odor to oncology: non-canonical odorant receptors in cancer

and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer

founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer

Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling

Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer

for a number of inflammatory diseases including atherosclerosis, scleroderma, multiple sclerosis and cancer and efficiently advance a diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer